Oncology

Pancreatic cancer
#FDA #Oncology #Pancreatic cancer #Revolution Medicines

FDA approves RAS-targeted drug for metastatic pancreatic cancer

The US Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC).  It is approved in patients who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.  The… Read More

#Editor's Choice #News #Regulatory

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Clinical trial #HaemaLogiX #Oncology

KOALA trial launched to assess CAR-T for myeloma

The first patient has been dosed with PMCC-COE-KMA, an investigational CAR T-cell therapy being developed by Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy (CoE) and licensed by Australian biotechnology company HaemaLogiX.  The KOALA trial will evaluate the safety and efficacy of PMCC-COE-KMA in patients… Read More

#Cancer Research #News

Bispecific antibodies
#Bispecific Antibodies #European Commission #Johnson & Johnson #Myeloma #Oncology

EC okays immunotherapy double regimen for multiple myeloma

The European Commission (EC) has approved Johnson & Johnson’s Tecvayli (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care.  The indication extension in combination with daratumumab is approved for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least… Read More

#News #Regulatory

Map of China
#CAR-T #Cell therapy #China #Oncology #Solid tumours

When the world’s first solid-tumour CAR-T gets approved in China

In June 2026, China's National Medical Products Administration cleared satricabtagene autoleucel (satri-cel), CARsgen's Claudin18.2 CAR-T, for advanced gastric cancer. It became the world's first CAR-T cell therapy approved for a solid tumour. The science is genuinely impressive. But the geography is the story. Satri-cel is not a Chinese drug that… Read More

#Exclusive Content #Opinion #Regulatory

Colon cancer
#Colorectal cancer #Epigenetics #Juntendo University #Oncology

Study reveals how IL-26 reprogrammes colorectal cancer cells

Researchers have identified inflammatory cytokine interleukin-26 (IL-26) as a factor that acts on cancer cells and induces epigenetic reprogramming, promoting immune evasion.  While cancer cells acquire malignant traits through epigenetic remodelling, it remains unclear how immune-derived inflammatory factors regulate the epigenetics of colorectal cancer cells.  … Read More

#Cancer Research #News #Trending News

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Oncology #Pancreatic cancer #The University of Texas at Austin

Research uncovers driver of CAR-T resistance in solid tumours

Pancreatic tumours can resist immunotherapy by recruiting nearby immune cells, according to new research, which has revealed a potential new strategy for overcoming resistance in cell therapies.  CAR T-cell therapy has transformed treatment for several blood cancers but has repeatedly stalled against solid tumours such as pancreatic… Read More

#Cancer Research #Editor's Choice #News

Antibody-drug conjugate
#ADC #Antibodies #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Gilead Sciences #Nucleai #Oncology

Nucleai and Gilead Sciences enter oncology ADC collaboration

Nucleai and Gilead Sciences have entered an ongoing translational research collaboration, supporting Nucleai’s global antibody-drug conjugate (ADC) clinical development programmes. Nucleai’s AI-powered platform analyses pathology images to provide quantitative insights into tissue biology. As part of its collaboration with Gilead, Nucleai has analysed a large dataset of hematoxylin and eosin… Read More

#News

Leukaemia
#Acute Myeloid Leukaemia #Cancer research #Drug discovery #Oncology

New drug target discovered for acute myeloid leukaemia 

Researchers have identified a new target for an aggressive type of blood cancer, offering a promising treatment option that could keep patients well for longer, with fewer side effects.  Scientists at The Institute of Cancer Research, London, and The University of Edinburgh, discovered that blocking the TUT4/7 enzymes can significantly halt… Read More

#News

#Brain cancer #Chemotherapy #Oncology #The University of Manchester

Glioblastoma therapy timing could be key to treatment

Scientists have identified a brief window after brain tumour surgery during which a treatment for glioblastoma can cross the brain’s protective barrier and reach the cancer cells most likely to trigger tumour regrowth.  The discovery could pave the way for more effective treatments for glioblastoma, the most… Read More

#Cancer Research #Editor's Choice #News

Cancer tumour
#Cancer vaccines #Clinical trials #Drug discovery #Oncology

Trial will assess precision therapeutic vaccine in oesophageal cancer 

Infinitopes has announced that the first patient has been dosed with ITOP1, the company’s lead investigational therapeutic cancer vaccine candidate.  This marks the first clinical evaluation of Infinitopes’ Precision Immunomics platform, which combines large-scale immunopeptidomic antigen discovery with engineered viral vector technologies, to identify naturally presented tumour antigens capable of generating durable anti-tumour T-cell responses. Read More

#News

Heavy-chain-only antibody
#Antibody #Cancer Research UK #KisoJi Biotechnology #Oncology #Phase I trial

First patient receives novel heavy-chain-only antibody

Cancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours.  The study will evaluate the effectiveness and safety of KisoJi’s lead asset, KJ-103, a naked anti-TROP2 antibody.  TROP2 is a transmembrane glycoprotein involved in… Read More

#Cancer Research #News

Cytokine release syndrome
#Clinical trial #Cytokine Release Syndrome (CRS) #Immunotherapy #Myeloma #Oncology

New drug could improve access to immunotherapies

A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma.  The trial, called TOPICAL, is led by The Christie NHS Foundation Trust and will take… Read More

#Cancer Research #News

Radioactive containers
#Oncoinvent #Oncology #Phase I trial #Radiopharmaceuticals

Radiotherapeutic study shows low exposure to healthy organs

Radiopharmaceuticals company Oncoinvent has announced the publication of clinical dosimetry data for Radspherin in ovarian and colorectal cancer in the Journal of Nuclear Medicine.  The publication reports results from nine patients enrolled in the dosimetry cohorts of the Phase I Radspherin studies, which… Read More

#Cancer Research #News

T cells attacking cancer
#Cancer Research UK Manchester Institute #Dendritic cells #Immunotherapy #Oncology

Scientists unmask immune cells that supercharge the fight against cancer

A little‑known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester’s Cancer Research UK Manchester Institute, have found. Their discovery, published in Immunity, centres on activated dendritic cells, a specialised population of immune cells that orchestrate the body’s… Read More

#Cancer Research #Editor's Choice #News

Breast cancer
#Breast cancer #Oncology #Roswell Park Comprehensive Cancer Center #Sethera Therapeutics

Award validates collaborative breast cancer research project

A collaborative breast cancer research project has received funding through the Fiscal Year 2025 Breast Cancer Research Program Breakthrough Award, administered by the Congressionally Directed Medical Research Programs (CDMRP).   The award recognises the scientific merit, innovation, and collaborative strength of the research teams led by Dr Katerina… Read More

#Cancer Research #News

X-ray showing colon cancer
#Dispatch Bio #Gastrointestinal cancer #Immunotherapy #Oncology #Phase I trial #Solid tumours

New therapy targets blocks to immunotherapy success in solid tumours

Dispatch Bio has dosed the first participant in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, oesophageal adenocarcinoma, and gastroesophageal adenocarcinoma.   The participant was treated with both DV-10 and ide-cel… Read More

#Cancer Research #News